173 related articles for article (PubMed ID: 23970648)
1. Rash and hepatitis within days of starting a new antiretroviral regimen: nevirapine hypersensitivity, secondary syphilis or both?
Saxon CJ; Helbert MR; Komolafe AJ; Higgins SP
Int J STD AIDS; 2014 Mar; 25(3):228-30. PubMed ID: 23970648
[TBL] [Abstract][Full Text] [Related]
2. Determinants of nevirapine hypersensitivity and its effect on the association between hepatitis C status and mortality in antiretroviral drug-naive HIV-positive patients.
Phillips E; Gutiérrez S; Jahnke N; Yip B; Lima VD; Hogg RS; Harrigan PR; Montaner JS
AIDS; 2007 Jul; 21(12):1561-8. PubMed ID: 17630551
[TBL] [Abstract][Full Text] [Related]
3. Nevirapine-associated rash in a Jamaican child with HIV/AIDS.
Steel-Duncan JC; Pierre R; Gabay L; Christie CD
West Indian Med J; 2004 Oct; 53(5):356-8. PubMed ID: 15675504
[TBL] [Abstract][Full Text] [Related]
4. Incidence and risk factors for nevirapine-associated rash.
de Maat MM; ter Heine R; Mulder JW; Meenhorst PL; Mairuhu AT; van Gorp EC; Huitema AD; Beijnen JH
Eur J Clin Pharmacol; 2003 Sep; 59(5-6):457-62. PubMed ID: 12920493
[TBL] [Abstract][Full Text] [Related]
5. Nevirapine-associated hepatotoxicity was not predicted by CD4 count ≥250 cells/μL among women in Zambia, Thailand and Kenya.
Peters PJ; Stringer J; McConnell MS; Kiarie J; Ratanasuwan W; Intalapaporn P; Potter D; Mutsotso W; Zulu I; Borkowf CB; Bolu O; Brooks JT; Weidle PJ
HIV Med; 2010 Nov; 11(10):650-60. PubMed ID: 20659176
[TBL] [Abstract][Full Text] [Related]
6. Predicting factors for unsuccessful switching from nevirapine to efavirenz in HIV-infected patients who developed nevirapine-associated skin rash.
Kiertiburanakul S; Malathum K; Watcharananan S; Sathapatayavongs B; Sungkanuparph S
Int J STD AIDS; 2009 Mar; 20(3):176-9. PubMed ID: 19255265
[TBL] [Abstract][Full Text] [Related]
7. DRESS (drug rash with eosinophilia and systemic symptoms) syndrome associated with nevirapine therapy.
Bourezane Y; Salard D; Hoen B; Vandel S; Drobacheff C; Laurent R
Clin Infect Dis; 1998 Nov; 27(5):1321-2. PubMed ID: 9827291
[No Abstract] [Full Text] [Related]
8. Hypersensitivity syndrome (DRESS) and meningoencephalitis associated with nevirapine therapy.
Lanzafame M; Rovere P; De Checchi G; Trevenzoli M; Turazzini M; Parrinello A
Scand J Infect Dis; 2001; 33(6):475-6. PubMed ID: 11450872
[TBL] [Abstract][Full Text] [Related]
9. Issues in antiretroviral toxicity.
Boyle BA
AIDS Read; 2003 Oct; 13(10):459, 463-4, 468-9, 479. PubMed ID: 14596223
[No Abstract] [Full Text] [Related]
10. [Favorable new data for nevirapine. Antiretroviral effect confirmed--and also lipid profile].
MMW Fortschr Med; 2004 Apr; 146 Spec No 1():58-60. PubMed ID: 15373051
[No Abstract] [Full Text] [Related]
11. HLA-B*3505 allele is a strong predictor for nevirapine-induced skin adverse drug reactions in HIV-infected Thai patients.
Chantarangsu S; Mushiroda T; Mahasirimongkol S; Kiertiburanakul S; Sungkanuparph S; Manosuthi W; Tantisiriwat W; Charoenyingwattana A; Sura T; Chantratita W; Nakamura Y
Pharmacogenet Genomics; 2009 Feb; 19(2):139-46. PubMed ID: 19104471
[TBL] [Abstract][Full Text] [Related]
12. Incidence and risk factors of rash associated with efavirenz in HIV-infected patients with preceding nevirapine-associated rash.
Manosuthi W; Thongyen S; Chumpathat N; Muangchana K; Sungkanuparph S
HIV Med; 2006 Sep; 7(6):378-82. PubMed ID: 16903982
[TBL] [Abstract][Full Text] [Related]
13. Nevirapine-associated rash with eosinophilia and systemic symptoms in a child with human immunodeficiency virus infection.
Santos RP; Ramilo O; Barton T
Pediatr Infect Dis J; 2007 Nov; 26(11):1053-6. PubMed ID: 17984815
[TBL] [Abstract][Full Text] [Related]
14. Clinical toxicity of highly active antiretroviral therapy in a home-based AIDS care program in rural Uganda.
Forna F; Liechty CA; Solberg P; Asiimwe F; Were W; Mermin J; Behumbiize P; Tong T; Brooks JT; Weidle PJ
J Acquir Immune Defic Syndr; 2007 Apr; 44(4):456-62. PubMed ID: 17279048
[TBL] [Abstract][Full Text] [Related]
15. Oral adverse effects due to the use of Nevirapine.
Moura MD; Senna MI; Madureira DF; Fonseca LM; Mesquita RA
J Contemp Dent Pract; 2008 Jan; 9(1):84-90. PubMed ID: 18176653
[TBL] [Abstract][Full Text] [Related]
16. Efficacy and tolerability of nevirapine- versus efavirenz-containing regimens in HIV-infected Thai children.
Lapphra K; Vanprapar N; Chearskul S; Phongsamart W; Chearskul P; Prasitsuebsai W; Chokephaibulkit K
Int J Infect Dis; 2008 Nov; 12(6):e33-8. PubMed ID: 18573672
[TBL] [Abstract][Full Text] [Related]
17. Nevirapine-related adverse events in a patient receiving a fixed-drug combination pill.
Daniel OJ; Krain AB; Ogun SA; Odusoga OL; Boyle BA
J Natl Med Assoc; 2005 Dec; 97(12):1719-21. PubMed ID: 16396066
[TBL] [Abstract][Full Text] [Related]
18. Efavirenz replacement by immediate full-dose nevirapine is safe in HIV-1-infected patients in Cambodia.
Laureillard D; Prak N; Fernandez M; Ngeth C; Moeung S; Riel V; Chhneang V; Song S; Quillet C; Piketty C
HIV Med; 2008 Aug; 9(7):514-8. PubMed ID: 18554312
[TBL] [Abstract][Full Text] [Related]
19. Safety of nevirapine in pregnancy.
Natarajan U; Pym A; McDonald C; Velisetty P; Edwards SG; Hay P; Welch J; de Ruiter A; Taylor GP; Anderson J
HIV Med; 2007 Jan; 8(1):64-9. PubMed ID: 17305934
[TBL] [Abstract][Full Text] [Related]
20. Stavudine plus didanosine and nevirapine in antiretroviral-naive HIV-infected adults: preliminary safety and efficacy results. VIRGO Study Team.
Raffi F; Reliquet V; Francois C; Garre M; Hascoet C; Allavena C; Arvieux C; Breux JP; Perre P; Rozenbaum W; Auger S
Antivir Ther; 1998; 3 Suppl 4():57-60. PubMed ID: 10723512
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
